Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 117.62 USD 12.26% Market Closed
Market Cap: 7.8B USD

Net Margin
Rhythm Pharmaceuticals Inc

-113.4%
Current
-375%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-113.4%
=
Net Income
-197.7m
/
Revenue
174.3m

Net Margin Across Competitors

No Stocks Found

Rhythm Pharmaceuticals Inc
Glance View

Market Cap
7.8B USD
Industry
Biotechnology

Rhythm Pharmaceuticals Inc. emerged with a resolute focus, aiming to transform the landscape for individuals grappling with rare genetic disorders of obesity. Founded on the premise that certain predispositions to obesity are deeply rooted in genetics, Rhythm embarked on a journey to develop treatments that target the melanocortin-4 receptor (MC4R) pathway. This pathway plays a critical role in regulating hunger, energy expenditure, and overall body weight. Their flagship product, Imcivree (setmelanotide), gained approval and marked a significant stride forward for the company. It is specifically designed to address the underlying genetic causes of obesity, offering hope to patients who previously had limited therapeutic options. The business model of Rhythm Pharmaceuticals is patient-centric, grounded in innovation and strategic collaborations. They generate revenue through the commercialization of Imcivree, facilitated by partnerships with healthcare providers and institutions that benefit from the specialized treatment they offer. Additionally, Rhythm actively invests in research and development, continually seeking to expand the applicability of their products to other genetic obesity-related conditions. By maintaining a robust pipeline and leveraging scientific advancements, the company positions itself as a pioneer in addressing an underserved niche, sustainably growing through targeted drug development and market expansion initiatives.

RYTM Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-113.4%
=
Net Income
-197.7m
/
Revenue
174.3m
What is the Net Margin of Rhythm Pharmaceuticals Inc?

Based on Rhythm Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -113.4%.

Back to Top